Female genitourinary fistula repair is organized by the tract involved (vesicovaginal, ureterovaginal, urethrovaginal, vesicouterine, rectovaginal) and by the surgical approach that accesses it best. The recurring decisions are route (transvaginal vs. transabdominal vs. combined), timing (immediate vs. early vs. delayed), interposition flap need (none vs. Martius vs. gracilis vs. omentum), and whether a protective diversion is required.
In developed countries, female GU fistulas are predominantly iatrogenic — hysterectomy is the leading cause (58–66%), followed by other pelvic surgery (26%) and obstetric injury (12%). In low- and middle-income countries, prolonged obstructed labor remains the dominant etiology (Wall 2006). The four pathophysiologic factors that prevent spontaneous closure — distal obstruction, foreign body, granuloma, and tract epithelialization — make conservative management successful only in a narrow window of small, fresh, simple fistulas. Transvaginal repair is the preferred default when accessible, with the Latzko partial colpocleisis and Sims-Simon multi-layered closure as the workhorse vaginal techniques (89–100% primary success in non-irradiated VVF). Transabdominal repair (open, laparoscopic, or robotic O'Conor) is reserved for high / inaccessible fistulas, those near the ureteral orifices requiring reimplantation, complex radiation fistulas requiring vascularized abdominal flaps, or failed transvaginal repair. Tissue interposition is unnecessary for most simple non-irradiated fistulas (closure >90% without flap) but essential for radiation, recurrent, or significant-tissue-loss fistulas.
| Presentation | Most Likely Fistula | Key Diagnostic Test |
|---|
| Continuous urinary leakage per vagina + positive bladder dye test | VVF (vesicovaginal) | Cystoscopy + dye test |
| Continuous urinary leakage + negative bladder dye test + hydronephrosis / flank pain | UretVF (ureterovaginal) | CT urogram; retrograde pyelogram |
| Urinary leakage worsened by Valsalva + periurethral defect | UVF (urethrovaginal) | Cystourethroscopy; EUA with metal sound |
| Cyclical hematuria (menouria) ± amenorrhea after C-section | VUF (vesicouterine; Youssef syndrome) | Hysteroscopy with dye; cystoscopy; MRI |
| Passage of flatus / stool per vagina + foul vaginal discharge | RVF (rectovaginal) | Anoscopy; endoanal US or MRI; EUA |
| Continuous urinary ± fecal leakage after prolonged obstructed labor (LMIC setting) | Obstetric fistula (VVF ± RVF ± urethral damage) | Pelvic exam; Goh classification; cystoscopy |
| Fistula | Conservative Option | Selection Criteria | Expected Success |
|---|
| VVF | Conservative management — continuous Foley × 4–8 wk + anticholinergics ± vaginal estrogen | Small (< 5 mm), fresh, simple, non-irradiated, iatrogenic etiology | Up to 92.9% in highly selected; minority in unselected |
| VVF | Endoscopic management (Bugbee fulguration, Ho:YAG laser, tissue adhesives, transvesicoscopic / V-NOTES / lap or robotic) + 2–3 wk Foley | ≤ 3.5 mm fulguration; ≤4 mm laser; <1 cm tissue adhesives; larger lesions via lap / robotic / V-NOTES | 73–100% by approach |
| UretVF | Ureteral stent × 6 wk (AUA Urotrauma 2020 — first-line) | Stent-passable lesion; retrograde or antegrade access | 64–100% |
| VUF | Foley drainage ± hormonal suppression (GnRH-a) | Small (< 5 mm), early diagnosis | Limited data; case reports |
| UVF | Not typically amenable to conservative management | — | — |
| Clinical Scenario | Recommended Approach | Technique | Success Rate |
|---|
| Simple post-hysterectomy VVF, non-irradiated | Transvaginal (preferred) | Latzko partial colpocleisis or Sims-Simon multi-layered; ± Martius flap | 89–100% |
| VVF near ureteral orifices, high, or inaccessible | Transabdominal | O'Conor transvesical (open / laparoscopic / robotic) ± omental interposition | 91–100% |
| Radiation-induced VVF (RVVF) | Individualized | Vaginal + Martius; or abdominal + omental / rectus abdominis flap; 70% may require urinary diversion | 20–48% primary; 80% cumulative |
| Recurrent VVF after failed repair | Repeat vaginal acceptable; consider abdominal if vaginal failed | Add tissue interposition if not used initially | 72–83% secondary |
| Trigonal VVF | Transabdominal preferred | Transvesical with ureteral reimplantation if needed | ~68% |
| UretVF, stent placement feasible | Endoscopic (first-line) | Retrograde JJ stent × 6 wk | 64–100% |
| UretVF, stent failure | Surgical reconstruction | Ureteroneocystostomy ± psoas hitch / Boari flap (open / robotic) | ~100% |
| UVF | Transvaginal layered repair ± Martius flap | Multi-layered closure; labial pedicle flap urethroplasty for complex cases with stricture | 90–100% primary; 52% develop post-repair SUI |
| VUF (Youssef syndrome) | Transabdominal (open / robotic / laparoscopic) — or transvaginal | Fistula excision; double-layer bladder closure; uterine-sparing when fertility desired | 100% first attempt |
| Obstetric VVF, Goh Type 1–2 | Transvaginal layered repair | Tension-free, watertight; 14-day catheter drainage | 83–88% first attempt |
| Obstetric VVF, Goh Type 3–4 (urethral involvement, circumferential) | Transvaginal + tissue interposition (Martius) ± urethroplasty | Adjuncts (PRP, SIS, buccal graft) for severe cases; counsel re: post-repair SUI | Lower; staged approach common |
| Post-obstetric persistent SUI after closure | Bulking → pubovaginal sling | Bulkamid (72%) → autologous PVS (91%) | 16–55% develop persistent SUI |
| Clinical Scenario | Recommended Intervention | Key Considerations |
|---|
| Acute obstetric RVF | Nonoperative management 3–6 mo (sitz baths, fiber, wound care) | 52–66% heal without surgery |
| Simple low RVF, intact sphincter | Endorectal advancement flap (ERAF) | ASCRS 2022 procedure of choice; 41–78% success; stoma not routinely needed |
| Low RVF + sphincter defect | ERAF + sphincteroplasty ± levatorplasty; or episioproctotomy | Sphincteroplasty improves healing to 80%; episioproctotomy 78–100% |
| Recurrent / complex RVF | Martius flap (first-line interposition) | 65–94% success; shorter LOS than gracilis; stoma often unnecessary (Pastier 2024) |
| RVF after Martius failure | Gracilis muscle interposition | Pooled 64% success; longer LOS; SSI 32%; reserve as salvage |
| Anastomotic RVF (post-colorectal surgery) | Fecal diversion → transabdominal repair (resection + coloanal anastomosis, DCAA/Turnbull-Cutait, sleeve excision, lap omentoplasty, or APR) | 37% heal with diversion alone; major procedure (OR 6.4) and diverting stoma (OR 3.5) independently predict success |
| Crohn's-related RVF | Medical therapy first (infliximab ± immunomodulator); seton for drainage; surgical repair only after endoscopic mucosal healing | ACG 2025: anti-TNF + advancement flap improves long-term healing; proctectomy as last resort |
| Radiation-induced RVF | Tissue interposition mandatory (Martius or gracilis); consider diversion | Martius 92–93% in radiation RVF; gracilis as salvage; GRECCAR delayed-coloanal for failed primary |
For universal surgical principles (tension-free / watertight closure, tissue-interposition criteria, postoperative drainage, timing of repair, and the "first operation has the best chance" rule), and for the transvaginal-vs-transabdominal approach-selection cheat-sheet, see the Principles of Fistula Repair article — these apply across all patients.